Company intelligence
Axion BioSystems
Imagine • Explore • Discover
About Axion BioSystems
Axion BioSystems’ suite of live-cell analysis tools offers next-generation solutions for continuous, noninvasive monitoring of in vitro cell models on your benchtop or inside your incubator. From investigating disease mechanisms in neurology and cardiology to developing lifesaving immunotherapies and antivirals, Axion’s award-winning products are designed to accelerate scientific breakthroughs and transform therapeutic development from discovery to manufacturing. Since launching the revolutionary Maestro multielectrode array (MEA) system in 2008, Axion has continuously expanded its offerings, introducing the premier live-cell analyzer Maestro Z in 2019 and the automated live-cell Omni imager in 2023. Featuring real-time, label-free monitoring, powerful software, and scalable throughput, discover how Axion’s user-friendly tools can simplify the workflow in any academic, biotechnology, or pharmaceutical lab. Promoting a culture of collaboration, innovation, inclusivity, and customer commitment, Axion BioSystems has more than 180 employees worldwide and is headquartered in the tech hub of Atlanta, Georgia, USA.
Verified activity
Signals from Axion BioSystems
6 published signals
Research & Knowledge
Axion BioSystems used the label-free Maestro Z system to measure real-time cytotoxicity against VIP-expressing pancreatic tumor cells.
Reported by Axion BioSystems
Research & Knowledge
Axion BioSystems published research showing that CAR T cells engineered to secrete a vasoactive intestinal peptide receptor antagonist secrete a short antagonist peptide designed to block VIP-VIPR signaling locally.
Reported by Axion BioSystems
Presence & Recognition
Axion BioSystems announced that Mike Clements will present an on-demand webinar on the Maestro and MEA tools for drug development.
Reported by Anthony Schramm
Research & Knowledge
Axion BioSystems used the Maestro Pro MEA system to show that NGF-matured iPruriceptors increased mean firing rate in response to itch-related stimuli including histamine, IL-31, and IL-13.
Reported by Axion BioSystems
Research & Knowledge
Axion BioSystems published a study by Hisato I., Ruiqi Hu, Xu Li, Erdene Baljinnyam, Brian S. Kim, and Samuele Marro developing a protocol to generate human iPSC-derived pruriceptors, or iPruriceptors.
Reported by Axion BioSystems
Research & Knowledge
Axion BioSystems published a webinar on the LEAP™ workflow for examining action potential waveforms in hERG channel inhibition.
Reported by Axion BioSystems